Even though an estimated 10–20 million people worldwide are infected with the oncogenic
retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly …

It has been nearly 40 years since human T-cell leukemia virus-1 (HTLV-1), the first
oncogenic retrovirus in humans and the first demonstrable cause of cancer by an infectious …

Five to ten million individuals are infected by Human T-cell Leukemia Virus type 1 (HTLV-1).
HTLV-1 is transmitted through prolonged breast-feeding, by sexual contacts and by …

Human T-lymphotropic virus type 1 (HTLV-1) is estimated to affect 5 to 10 million people
globally and can cause severe and potentially fatal disease, including adult T-cell …

Human T-cell leukaemia virus 1 (HTLV-1) is the most potent carcinogenic oncovirus and
potentially the most oncogenic risk factor including chem ical carcinogens. 1 A unique and …

Going back to their discovery in the early 1980s, both the Human T-cell Leukemia virus type-
1 (HTLV-1) and the Human Immunodeficiency Virus type-1 (HIV-1) greatly fascinated the …

Human T lymphotropic virus type 1 (HTLV-1) is a retrovirus that causes lifelong T-cell
infection in humans, impacting the host immune response. This virus causes a range of …

Human T-cell leukemia virus type 1 (HTLV-1) is a replication-competent human retrovirus
associated with two distinct types of diseases: a malignancy of mature CD4+ T cells called …

Human T-cell leukemia virus type 1 (HTLV-1) is an oncogenic human retrovirus which
causes a lifelong infection. An estimated 5–10 million persons are infected with HTLV-1 …

Human T cell leukemia virus type 1 (HTLV-1) was the first discovered human retrovirus and
the etiologic agent of adult T-cell leukemia and HTLV-1-associated myelopathy/tropical …